Patología dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacológico

Pilar Alejandra Sáiz Martínez; Pilar Alejandra Sáiz Martínez; Pilar Alejandra Sáiz Martínez; Luis Jimenez Treviño; Luis Jimenez Treviño; Eva Mª Díaz Mesa; Eva Mª Díaz Mesa; Mª Paz García-Portilla González; Mª Paz García-Portilla González; Mª Paz García-Portilla González; Pedro Marina González; Pedro Marina González; Susana Al-Halabí; Susana Al-Halabí; Néstor Szerman; Néstor Szerman; Julio Bobes García; Julio Bobes García; Julio Bobes García; Pedro Ruiz

doi:10.20882/adicciones.7

Patología dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacológico

Pilar Alejandra Sáiz Martínez, Pilar Alejandra Sáiz Martínez, Pilar Alejandra Sáiz Martínez, Luis Jimenez Treviño, Luis Jimenez Treviño, Eva Mª Díaz Mesa, Eva Mª Díaz Mesa, Mª Paz García-Portilla González, Mª Paz García-Portilla González, Mª Paz García-Portilla González, Pedro Marina González, Pedro Marina González, Susana Al-Halabí, Susana Al-Halabí, Néstor Szerman, Néstor Szerman, Julio Bobes García, Julio Bobes García, Julio Bobes García, Pedro Ruiz

Psychiatry & Behavioral Sciences

Research output: Contribution to journal › Article

5 Scopus citations

Abstract

Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.

Original language	English (US)
Article number	A254
Pages (from-to)	254-274
Number of pages	21
Journal	Adicciones
Volume	26
Issue number	3
DOIs	https://doi.org/10.20882/adicciones.7
State	Published - Jan 1 2014

Keywords

Anxiety disorders
Comorbidity
Dual diagnosis
Recommendations
Therapeutics

ASJC Scopus subject areas

Medicine (miscellaneous)
Psychiatry and Mental health

Access to Document

10.20882/adicciones.7

Fingerprint Dive into the research topics of 'Patología dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacológico'. Together they form a unique fingerprint.

Cite this

Sáiz Martínez, P. A., Sáiz Martínez, P. A., Sáiz Martínez, P. A., Treviño, L. J., Treviño, L. J., Díaz Mesa, E. M., Díaz Mesa, E. M., García-Portilla González, M. P., García-Portilla González, M. P., García-Portilla González, M. P., González, P. M., González, P. M., Al-Halabí, S., Al-Halabí, S., Szerman, N., Szerman, N., García, J. B., García, J. B., García, J. B., & Ruiz, P. (2014). Patología dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacológico. Adicciones, 26(3), 254-274. [A254]. https://doi.org/10.20882/adicciones.7

Patología dual en trastornos de ansiedad : Recomendaciones en el tratamiento farmacológico. / Sáiz Martínez, Pilar Alejandra; Sáiz Martínez, Pilar Alejandra; Sáiz Martínez, Pilar Alejandra; Treviño, Luis Jimenez; Treviño, Luis Jimenez; Díaz Mesa, Eva Mª; Díaz Mesa, Eva Mª; García-Portilla González, Mª Paz; García-Portilla González, Mª Paz; García-Portilla González, Mª Paz; González, Pedro Marina; González, Pedro Marina; Al-Halabí, Susana; Al-Halabí, Susana; Szerman, Néstor; Szerman, Néstor; García, Julio Bobes; García, Julio Bobes; García, Julio Bobes; Ruiz, Pedro.

In: Adicciones, Vol. 26, No. 3, A254, 01.01.2014, p. 254-274.

Research output: Contribution to journal › Article

Sáiz Martínez, PA, Sáiz Martínez, PA, Sáiz Martínez, PA, Treviño, LJ, Treviño, LJ, Díaz Mesa, EM, Díaz Mesa, EM, García-Portilla González, MP, García-Portilla González, MP, García-Portilla González, MP, González, PM, González, PM, Al-Halabí, S, Al-Halabí, S, Szerman, N, Szerman, N, García, JB, García, JB, García, JB & Ruiz, P 2014, 'Patología dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacológico', Adicciones, vol. 26, no. 3, A254, pp. 254-274. https://doi.org/10.20882/adicciones.7

Sáiz Martínez, Pilar Alejandra ; Sáiz Martínez, Pilar Alejandra ; Sáiz Martínez, Pilar Alejandra ; Treviño, Luis Jimenez ; Treviño, Luis Jimenez ; Díaz Mesa, Eva Mª ; Díaz Mesa, Eva Mª ; García-Portilla González, Mª Paz ; García-Portilla González, Mª Paz ; García-Portilla González, Mª Paz ; González, Pedro Marina ; González, Pedro Marina ; Al-Halabí, Susana ; Al-Halabí, Susana ; Szerman, Néstor ; Szerman, Néstor ; García, Julio Bobes ; García, Julio Bobes ; García, Julio Bobes ; Ruiz, Pedro. / Patología dual en trastornos de ansiedad : Recomendaciones en el tratamiento farmacológico. In: Adicciones. 2014 ; Vol. 26, No. 3. pp. 254-274.

@article{fe6d2f8110f44722a68edde67ad5a381,

title = "Patolog{\'i}a dual en trastornos de ansiedad: Recomendaciones en el tratamiento farmacol{\'o}gico",

abstract = "Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.",

keywords = "Anxiety disorders, Comorbidity, Dual diagnosis, Recommendations, Therapeutics",

author = "{S{\'a}iz Mart{\'i}nez}, {Pilar Alejandra} and {S{\'a}iz Mart{\'i}nez}, {Pilar Alejandra} and {S{\'a}iz Mart{\'i}nez}, {Pilar Alejandra} and Trevi{\~n}o, {Luis Jimenez} and Trevi{\~n}o, {Luis Jimenez} and {D{\'i}az Mesa}, {Eva Mª} and {D{\'i}az Mesa}, {Eva Mª} and {Garc{\'i}a-Portilla Gonz{\'a}lez}, {Mª Paz} and {Garc{\'i}a-Portilla Gonz{\'a}lez}, {Mª Paz} and {Garc{\'i}a-Portilla Gonz{\'a}lez}, {Mª Paz} and Gonz{\'a}lez, {Pedro Marina} and Gonz{\'a}lez, {Pedro Marina} and Susana Al-Halab{\'i} and Susana Al-Halab{\'i} and N{\'e}stor Szerman and N{\'e}stor Szerman and Garc{\'i}a, {Julio Bobes} and Garc{\'i}a, {Julio Bobes} and Garc{\'i}a, {Julio Bobes} and Pedro Ruiz",

year = "2014",

month = jan,

day = "1",

doi = "10.20882/adicciones.7",

language = "English (US)",

volume = "26",

pages = "254--274",

journal = "Adicciones",

issn = "0214-4840",

publisher = "Edita Socidrogalcohol",

number = "3",

}

TY - JOUR

T1 - Patología dual en trastornos de ansiedad

T2 - Recomendaciones en el tratamiento farmacológico

AU - Sáiz Martínez, Pilar Alejandra

AU - Treviño, Luis Jimenez

AU - Díaz Mesa, Eva Mª

AU - García-Portilla González, Mª Paz

AU - González, Pedro Marina

AU - Al-Halabí, Susana

AU - Szerman, Néstor

AU - García, Julio Bobes

AU - Ruiz, Pedro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.

AB - Anxiety disorders and substance use disorders are highly comorbid (between 18% and 37%), and such comorbidity complicates treatment and worsens prognosis (including higher suicide risk). There are not many research works on the specific pharmacologic treatment of dual comorbid anxiety disorders. Most authors recommend a simultaneous approach of both, anxiety and substance use, disorders. Research data on pharmacotherapy suggest that psychotropics used in the treatment of anxiety disorders are also effective in dual diagnosis. SSRIs are considered first-line therapy in the treatment of dual anxiety while benzodiacepines should be avoided. New generation antiepileptic have shown efficacy in case series and open label studies in the latest years, thus being a promising treatment option for dual comorbid anxiety disorders, specially pregabalin in generalized anxiety disorder.

KW - Anxiety disorders

KW - Comorbidity

KW - Dual diagnosis

KW - Recommendations

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84922382863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922382863&partnerID=8YFLogxK

U2 - 10.20882/adicciones.7

DO - 10.20882/adicciones.7

M3 - Article

AN - SCOPUS:84922382863

VL - 26

SP - 254

EP - 274

JO - Adicciones

JF - Adicciones

SN - 0214-4840

IS - 3

M1 - A254

ER -